• John C Byrd, Richard R Furman, Steven E Coutre, Jan A Burger, Kristie A Blum, Morton Coleman, William G Wierda, Jeffrey A Jones, Weiqiang Zhao, Nyla A Heerema, Amy J Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F James, and Susan O'Brien.
• The Ohio State University, Columbus, OH;
• Blood. 2015 Apr 16;125(16):2497-506.

AbstractIbrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL). The durable responses observed with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period. We report on median 3-year follow-up of 132 patients with symptomatic treatment-naïve and relapsed/refractory CLL or small lymphocytic lymphoma. Longer treatment with ibrutinib was associated with improvement in response quality over time and durable remissions. Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections. Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease. Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 year and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better. Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.© 2015 by The American Society of Hematology.

37 keywords...

hide…